PMID- 16222731
OWN - NLM
STAT- MEDLINE
DCOM- 20060125
LR  - 20190430
IS  - 1007-9327 (Print)
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Linking)
VI  - 11
IP  - 35
DP  - 2005 Sep 21
TI  - Treatment of Zollinger-Ellison syndrome.
PG  - 5423-32
AB  - In this article, we have reviewed the main therapeutic measures for the treatment 
      of Zollinger-Ellison syndrome (ZES). Review of the literature was based on 
      computer searches (Pub-Med, Index Medicus) and personal experiences. We have 
      evaluated all the measures now available for treating patients with sporadic 
      gastrinomas or gastrinomas associated with Multiple Endocrine Neoplasia Type 1, 
      (MEN 1) including medical therapy such as antisecretory drugs and somatostatin 
      analogs (SST), chemotherapy and chemoembolization, and surgical procedures. In 
      ZES patients, the best therapeutic procedure is surgery which, if radical, can be 
      curative. Medical treatment can be the best palliative therapy and should be 
      used, when possible, in association with surgery, in a multimodal therapeutic 
      approach.
FAU - Tomassetti, Paola
AU  - Tomassetti P
AD  - Department of Internal Medicine and Gastroenterology, University of Bologna, 
      Policlinico S.Orsola-Malpighi, Via Massarenti, 9, 40138, Bologna, Italy. 
      paola.tomassetti@unibo.it
FAU - Campana, Davide
AU  - Campana D
FAU - Piscitelli, Lydia
AU  - Piscitelli L
FAU - Mazzotta, Elena
AU  - Mazzotta E
FAU - Brocchi, Emilio
AU  - Brocchi E
FAU - Pezzilli, Raffaele
AU  - Pezzilli R
FAU - Corinaldesi, Roberto
AU  - Corinaldesi R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Antacids)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
RN  - 51110-01-1 (Somatostatin)
RN  - 9008-11-1 (Interferons)
SB  - IM
MH  - Antacids/therapeutic use
MH  - Antineoplastic Agents/therapeutic use
MH  - Chemoembolization, Therapeutic
MH  - Helicobacter pylori/pathogenicity
MH  - Histamine H2 Antagonists/therapeutic use
MH  - Humans
MH  - Interferons/therapeutic use
MH  - Multiple Endocrine Neoplasia Type 1/complications
MH  - Proton Pump Inhibitors
MH  - Somatostatin/analogs & derivatives
MH  - Zollinger-Ellison Syndrome/complications/diagnosis/etiology/*therapy
PMC - PMC4320348
EDAT- 2005/10/14 09:00
MHDA- 2006/01/26 09:00
PMCR- 2005/09/21
CRDT- 2005/10/14 09:00
PHST- 2005/10/14 09:00 [pubmed]
PHST- 2006/01/26 09:00 [medline]
PHST- 2005/10/14 09:00 [entrez]
PHST- 2005/09/21 00:00 [pmc-release]
AID - 10.3748/wjg.v11.i35.5423 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2005 Sep 21;11(35):5423-32. doi: 10.3748/wjg.v11.i35.5423.